Piramal Pharma plans $40 million investment in technology

New Delhi: Piramal Enterprises' pharmaceutical solutions division has said it is planning to invest $40 million on new equipment and modern technologies.

"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as anti-body drug conjugation (ADC), advanced flow reactor (ARF) and biocatalysis centre of excellence systems," the pharma major said in a statement.

The investment has been planned with a view to enhance related infrastructure to accommodate the new technologies and equipment.

In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure, the release added. Recently, the company completed a green field facility (USD 10 million) to double its Discovery Services capacity, and also approved a $20 million capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing, the release said.

PEL is one of the leading global players in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.

The company said it has secured four awards in three key categories of quality, reliability, and regulatory at the recent CMO Leadership Awards held in Boston, USA.New Delhi: Piramal Enterprises' pharmaceutical solutions division has said it is planning to invest $40 million on new equipment and modern technologies.

"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as anti-body drug conjugation (ADC), advanced flow reactor (ARF) and biocatalysis centre of excellence systems," the pharma major said in a statement.

The investment has been planned with a view to enhance related infrastructure to accommodate the new technologies and equipment.

In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure, the release added. Recently, the company completed a green field facility (USD 10 million) to double its Discovery Services capacity, and also approved a $20 million capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing, the release said.

PEL is one of the leading global players in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.

The company said it has secured four awards in three key categories of quality, reliability, and regulatory at the recent CMO Leadership Awards held in Boston, USA.

Image: CorbisImages